On 6th November 2024, Remap Consulting hosted a compelling webinar as part of our EU HTA series, presenting ground-breaking insights and practical learnings from one of the pioneering Joint Scientific Consultations (JSCs). Led by Managing Directors Graham Foxon and Paul Craddy, this session offered a deep dive into the JSC process, featuring a real-world case study to illustrate the strategic importance and impact of early EU Health Technology Assessment (HTA) engagement.
This event provided invaluable insights for market access professionals, regulatory affairs specialists, and strategic planners, giving them the tools to navigate the shifting landscape of Joint Scientific Consultations with confidence.
To view the webinar on demand, please click below or here
If you have any questions or would like to discuss the topic in more detail, please reach out.
View our other webinars:
NICE’s Proportionate Approach to Technology Appraisals
Orphan Medicine Market Access in Europe
Implications of the EU HTA Process for Manufacturers
Are you ready for the new EU HTA in 2025?
EU HTA – moving from strategy to action
